|
2005/OB/07
|
OXFORD
BIOMEDICA ANNOUNCES BOARD APPOINTMENT
Oxford
BioMedica (LSE:OXB.L), the leading gene therapy company, today
announces that Nick Woolf has been promoted to the Board as
an executive director. He will maintain his title of Senior
Vice President for Corporate Strategy. His primary responsibilities
include corporate finance, M&A evaluation and corporate
communications as well as an important role, jointly with
Peter Nolan, in business development and deal negotiation.
Prior
to joining Oxford BioMedica in 2002, Nick spent eight years
as a top-rated biotechnology and pharmaceutical analyst. Nick
has been involved in all aspects of company financing, ranging
from IPOs to major corporate deals. He served as Director
and Head of European Biotechnology Research at ABN AMRO, and
was previously with Robertson Stephens International, Nomura
and SBC Warburg. Nick holds an MA from Oxford University in
Chemistry.
Commenting
on the Board appointment, Professor Alan Kingsman, Chief Executive
of Oxford BioMedica, said: “Nick has contributed at
a very high level to all corporate activities and has been
instrumental in raising the company’s profile in the
industry and the investment community. We are delighted to
welcome him to the Board."
-
ends -
Return to the News
|
|
Notes
| 1. |
Oxford
BioMedica |
|
Oxford
BioMedica (LSE: OXB) is a biopharmaceutical
company specialising in the development
of novel gene-based therapeutics with a
focus on the areas of oncology and neurotherapy.
The Company was established in 1995 as a
spin out from Oxford University, and is
listed on the London Stock Exchange.
Oxford
BioMedica has core expertise in gene delivery,
as well as in-house clinical, regulatory
and manufacturing know-how. In oncology,
the pipeline includes an immunotherapy and
a gene therapy in multiple Phase II trials,
and a preclinical targeted antibody therapy
in collaboration with Wyeth. In neurotherapy,
the Company’s lead product is a gene
therapy for Parkinson’s disease, which
is expected to enter clinical development
in 2005, and four further preclinical candidates.
The Company is underpinned by over 80 patent
families, which represent one of the broadest
patent estates in the field.
The
Company has a staff of approximately 65
split between its main facilities in Oxford
and its wholly owned subsidiary, BioMedica
Inc, in San Diego, California. Oxford BioMedica
has corporate collaborations with Wyeth,
Intervet, Amersham, Viragen, MolMed and
Kiadis; and has licensed technology to a
number of companies including Merck &
Co and Biogen Idec.
|
| |
| For
further information please contact:
|
|
|
Oxford BioMedica plc
Professor Alan
Kingsman, Chief Executive
Andrew Wood, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
| City/Financial
Enquiries
Lisa
Baderoon/Mark
Court/Mary-Jane
Johnson
Buchanan Communications |
Tel: +44 (0)20 7466 5000
|
Scientific/Trade
Press Enquiries
Sue
Charles, Katja
Stout, Ashley
Lilly
College Hill - Life Sciences |
Tel:
+44 (0)20 7886 8150 |
|
|
|
|
|
Top
of page
Website by College Hill - Life Sciences
|
| |
|
|
